Therini Bio Raises Extra $39M In Series, A Round To Advance Clinical Trials For Neurodegenerative Disease Pipeline

Therini Bio, Inc., a clinical-stage biotech company focused on developing fibrin-targeting immunotherapies for neurodegenerative diseases caused by vascular dysfunction, has announced it raised $39 million in a Series A extension financing. This round included new investors Angelini Ventures and Apollo Health Ventures, in addition to existing investors such as SV Health Investors’ Biotech Fund, Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures, and Foundation for a Better World. With this extension, Therini Bio has increased its Series A total to $75 million.

The company plans to use the proceeds to fund Phase 1b trials for its lead candidate, THN391, which is being developed for the treatment of Alzheimer’s Disease (AD) and Diabetic Macular Edema (DME). The funds will also support the development of a fibrin/VEGF bispecific therapy. Therini Bio’s approach aims to address the root causes of neurodegeneration, which are often linked to vascular dysfunction driven by factors such as aging, genetics, hypertension, and diabetes. These conditions can lead to the accumulation of toxic fibrin deposits outside of blood vessels, triggering chronic neuroinflammation that damages neurons and contributes to severe neurodegenerative diseases.

Tara Nickerson, Ph.D., Chief Executive Officer of Therini Bio, “We are deeply grateful to partner with such a distinguished investor group, both new and old. Their support enables us to significantly advance our shared vision of delivering patients a rational, innovative approach to potentially treat their debilitating conditions, including Alzheimer’s disease and Diabetic Macular Edema. We look forward to advancing the Phase 1b trials to demonstrate the potential benefit of this novel mechanism in patients.”

Thomas Thestrup, Senior Principal at Angelini Ventures, mentioned, ”We are proud to support Therini Bio’s mission to address the underlying vascular and inflammatory drivers of neurodegenerative disease through a truly novel approach. As an active CNS investor, we are excited about Therini’s first-in-class selective antibody therapy targeting fibrin-mediated inflammation, offering a groundbreaking path to transform the treatment of diseases such as Alzheimer’s and DME.”

THN391, a potential first-in-class humanized monoclonal antibody, is designed to selectively block fibrin-mediated neuroinflammation without affecting the coagulation pathways. Preclinical studies have shown that THN391 prevents vascular and neuronal degeneration in models of AD and retinal diseases. In a recent Phase 1a trial, THN391 was well-tolerated in healthy volunteers, with no adverse hematological effects or impact on coagulation and fibrinolysis. The trial also showed no anti-drug antibody response, dose-proportional pharmacokinetics, and a half-life that supports monthly dosing. With this promising data and the recent funding, Therini Bio is preparing to begin dosing patients in Phase 1b trials to further evaluate THN391 in AD and DME.